Which has better earnings & valuation, ABBV or AMGN?

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $64.39B 7.23 $4.23B $3.54 74.45 Amgen $36.75B 6.23 $7.71B $16.09 26.33

Is ABBV or AMGN more profitable?

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Amgen 22.95% 124.14% 13.18%

Does the media favor ABBV or AMGN?

In the previous week, AbbVie had 11 more articles in the media than Amgen. MarketBeat recorded 39 mentions for AbbVie and 28 mentions for Amgen. AbbVie's average media sentiment score of 0.75 beat Amgen's score of 0.73 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 18 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 14 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Is ABBV or GILD more profitable?

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Gilead Sciences -10.64% -2.11% -0.75%

Does the media prefer ABBV or GILD?

In the previous week, AbbVie had 25 more articles in the media than Gilead Sciences. MarketBeat recorded 39 mentions for AbbVie and 14 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat AbbVie's score of 0.75 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 18 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MRNA or ABBV?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 41.78 -$2.82B -$7.99 N/A AbbVie $64.39B 7.23 $4.23B $3.54 74.45

Is MRNA or ABBV more profitable?

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% AbbVie 9.80% -422.07% 14.34%

Does the media prefer MRNA or ABBV?

In the previous week, Moderna had 9 more articles in the media than AbbVie. MarketBeat recorded 48 mentions for Moderna and 39 mentions for AbbVie. AbbVie's average media sentiment score of 0.75 beat Moderna's score of 0.33 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 10 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 4 Very Negative mention(s) Neutral AbbVie 18 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABBV or ABT?

In the previous week, AbbVie had 18 more articles in the media than Abbott Laboratories. MarketBeat recorded 39 mentions for AbbVie and 21 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.04 beat AbbVie's score of 0.75 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 18 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 14 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $64.39B 7.23 $4.23B $3.54 74.45 Astrazeneca $58.74B 4.34 $10.23B $6.69 24.56

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Astrazeneca 17.02% 31.45% 13.20%

Does the media favor ABBV or AZN?

In the previous week, AbbVie had 14 more articles in the media than Astrazeneca. MarketBeat recorded 39 mentions for AbbVie and 25 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.75 beat Astrazeneca's score of 0.61 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 18 Very Positive mention(s) 10 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 13 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

AbbVie (ABBV) Competitors

$263.54 -2.74 (-1.03%)

Closing price 03:59 PM Eastern

Extended Trading

$263.79 +0.25 (+0.09%)

As of 05:12 PM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? AbbVie's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AbbVie compare to Amgen?

AbbVie (NYSE:ABBV) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Amgen	22.95%	124.14%	13.18%

In the previous week, AbbVie had 11 more articles in the media than Amgen. MarketBeat recorded 39 mentions for AbbVie and 28 mentions for Amgen. AbbVie's average media sentiment score of 0.75 beat Amgen's score of 0.73 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	18 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	14 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45
Amgen	$36.75B	6.23	$7.71B	$16.09	26.33

AbbVie has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Amgen has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.4%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Amgen has raised its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

AbbVie currently has a consensus target price of $272.66, indicating a potential upside of 3.46%. Amgen has a consensus target price of $385.25, indicating a potential downside of 9.06%. Given AbbVie's stronger consensus rating and higher possible upside, research analysts plainly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Amgen	3 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.33

Summary

AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

AbbVie (NYSE:ABBV) and Gilead Sciences (NASDAQ:GILD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Gilead Sciences	-10.64%	-2.11%	-0.75%

In the previous week, AbbVie had 25 more articles in the media than Gilead Sciences. MarketBeat recorded 39 mentions for AbbVie and 14 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.96 beat AbbVie's score of 0.75 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	18 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.2% of AbbVie shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AbbVie has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

AbbVie currently has a consensus target price of $272.66, indicating a potential upside of 3.46%. Gilead Sciences has a consensus target price of $158.78, indicating a potential upside of 4.96%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has lower revenue, but higher earnings than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45
Gilead Sciences	$29.44B	6.37	$8.51B	-$2.67	N/A

Summary

AbbVie beats Gilead Sciences on 11 of the 19 factors compared between the two stocks.

How does AbbVie compare to Moderna?

Moderna (NASDAQ:MRNA) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Moderna has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Moderna had 9 more articles in the media than AbbVie. MarketBeat recorded 48 mentions for Moderna and 39 mentions for AbbVie. AbbVie's average media sentiment score of 0.75 beat Moderna's score of 0.33 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	10 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	4 Very Negative mention(s)	Neutral
AbbVie	18 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna currently has a consensus target price of $76.72, indicating a potential downside of 62.29%. AbbVie has a consensus target price of $272.66, indicating a potential upside of 3.46%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	14 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.12
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
AbbVie	9.80%	-422.07%	14.34%

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	41.78	-$2.82B	-$7.99	N/A
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45

Summary

AbbVie beats Moderna on 11 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

AbbVie (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abbott Laboratories has lower revenue, but higher earnings than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45
Abbott Laboratories	$44.33B	3.94	$6.52B	$3.09	32.69

AbbVie presently has a consensus price target of $272.66, suggesting a potential upside of 3.46%. Abbott Laboratories has a consensus price target of $119.50, suggesting a potential upside of 18.30%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.96

AbbVie has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

In the previous week, AbbVie had 18 more articles in the media than Abbott Laboratories. MarketBeat recorded 39 mentions for AbbVie and 21 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.04 beat AbbVie's score of 0.75 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	18 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	14 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Abbott Laboratories has a net margin of 11.65% compared to AbbVie's net margin of 9.80%. Abbott Laboratories' return on equity of 17.69% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Abbott Laboratories	11.65%	17.69%	9.44%

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.5%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years and Abbott Laboratories has raised its dividend for 54 consecutive years.

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AbbVie presently has a consensus price target of $272.66, indicating a potential upside of 3.46%. Astrazeneca has a consensus price target of $206.67, indicating a potential upside of 25.77%. Given Astrazeneca's higher probable upside, analysts plainly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

In the previous week, AbbVie had 14 more articles in the media than Astrazeneca. MarketBeat recorded 39 mentions for AbbVie and 25 mentions for Astrazeneca. AbbVie's average media sentiment score of 0.75 beat Astrazeneca's score of 0.61 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	18 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	13 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

AbbVie has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Astrazeneca	17.02%	31.45%	13.20%

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.23	$4.23B	$3.54	74.45
Astrazeneca	$58.74B	4.34	$10.23B	$6.69	24.56

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$465.62B	$3.94B	$7.26B	$22.74B
Dividend Yield	2.62%	3.63%	2.52%	3.68%
P/E Ratio	74.45	13.71	274.98	27.67
Price / Sales	7.23	1,310.42	606.85	20.20
Price / Cash	17.45	40.88	28.02	19.27
Price / Book	-144.01	15.34	10.50	4.64
Net Income	$4.23B	-$22.71M	$3.50B	$1.07B
7 Day Performance	-0.70%	-4.74%	-3.01%	-2.80%
1 Month Performance	2.91%	-8.32%	-4.15%	-5.85%
1 Year Performance	18.22%	27.18%	13.25%	5.75%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	3.8921 of 5 stars	$263.54 -1.0%	$272.66 +3.5%	+20.7%	$465.62B	$64.39B	74.45	57,000	Trending News
AMGN Amgen	3.4127 of 5 stars	$409.74 +0.9%	$383.46 -6.4%	+53.2%	$221.30B	$38.10B	25.44	31,500	Analyst Forecast
GILD Gilead Sciences	4.0474 of 5 stars	$149.17 -0.4%	$158.78 +6.4%	+35.8%	$184.79B	$30.46B	N/A	17,000
MRNA Moderna	1.9815 of 5 stars	$196.06 +0.6%	$76.72 -60.9%	+705.6%	$78.21B	$1.94B	N/A	4,700
ABT Abbott Laboratories	4.9491 of 5 stars	$101.54 +0.5%	$119.50 +17.7%	-24.5%	$175.70B	$44.33B	32.86	115,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors